Russell Investments Group, Ltd. Palatin Technologies Inc Transaction History

Russell Investments Group, Ltd.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$0.68 - $1.25 $41,285 - $75,892	-60,714 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$0.38 - $0.78 $135,960 - $279,077	-357,792 Reduced 85.49%	60,714 $41,000
Q3 2020 Nov 09, 2020	BUY	$0.47 - $0.64 $163,132 - $222,137	347,090 Added 486.01%	418,506 $198,000
Q2 2020 Aug 05, 2020	BUY	$0.41 - $0.73 $29,280 - $52,133	71,416 New	71,416 $36,000
Q2 2019 Aug 09, 2019	SELL	$0.98 - $1.64 $873,840 - $1.46 Million	-891,674 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$0.67 - $1.01 $175,925 - $265,201	262,576 Added 41.74%	891,674 $874,000
Q4 2018 Feb 11, 2019	BUY	$0.63 - $1.0 $348,257 - $552,789	552,789 Added 724.41%	629,098 $445,000
Q3 2018 Oct 26, 2018	BUY	$0.88 - $1.1 $67,151 - $83,939	76,309 New	76,309 $75,000
Q2 2018 Aug 08, 2018	SELL	$0.91 - $1.45 $42,970 - $68,469	-47,220 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$0.84 - $1.18 $39,664 - $55,719	47,220 New	47,220 $51,000
Q4 2017 Feb 06, 2018	SELL	$0.68 - $1.0 $153,167 - $225,246	-225,246 Closed	0 $0
Q3 2017 Nov 07, 2017	BUY	$0.39 - $0.66 $87,845 - $148,662	225,246	225,246 $149,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $8.83M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.